Investor Alert

New York Markets After Hours

Jan. 13, 2020, 8:25 a.m. EST

Dare Biosciences rockets on Bayer licensing deal

Watchlist Relevance

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

  • X
    Dare Bioscience Inc. (DARE)

or Cancel Already have a watchlist? Log In

By Chris Wack

Dare Bioscience Inc. /zigman2/quotes/203460984/composite DARE -3.25% shares rose 79% to $1.50 after the company said it is in a licensing agreement with Bayer (BAYN.XE).

Bayer may commercialize Dare's investigational contraceptive product Ovaprene in the U.S. once approved by the U.S. Food and Drug Administration, Dare said.

Dare said it is entitled to receive commercial milestone payments potentially totaling $310 million, in addition to double digit tiered royalties on sales.

Dare's Ovaprene is an investigational hormone-free monthly vaginal contraceptive currently in clinical development for the prevention of pregnancy.

Dare said it will receive an upfront payment and access to Bayer's clinical and market capabilities while retaining control over Ovaprene's development and regulatory approval process.

Bayer has the right to obtain exclusive rights to commercialize the product in the U.S. following completion of the pivotal clinical trial being undertaken by Dare.

If Bayer makes payment to Dare of $20 million, which Dare intends to apply to reimbursement of clinical study costs, then the exclusive license to commercialize Ovaprene in the U.S. will become effective.

Dare said it plans to file an investigational device exemption for Ovaprene in the first half of 2020 and, pending the U.S. Food and Drug Administration's review and clearance of the IDE, to initiate a pivotal contraceptive effectiveness and safety clinical study of Ovaprene in the second half of 2020.

Write to Chris Wack at chris.wack@wsj.com

US : U.S.: Nasdaq
$ 1.19
-0.04 -3.25%
Volume: 771,664
July 1, 2022 4:00p
P/E Ratio
Dividend Yield
Market Cap
$104.19 million
Rev. per Employee

This Story has 0 Comments
Be the first to comment
More News In

Story Conversation

Commenting FAQs »

Partner Center

Link to MarketWatch's Slice.